Stock listing
NYSE:RVTY Revvity, Inc. Stock
Home listing (NYSE) of Revvity, Inc.
Follow Revvity, Inc. into a list and get an email when it puts out news.
Share price · NYSE:RVTY
$145.22 USD -7.21 (-4.7%)
Close on Nov 20, 2026
- Day range
- $143.61 – $150.93 USDNov 20, 2026
- Volume
- 1.66M sharesNov 20, 2026
- Market cap
- $16.21B USDAt the close on Nov 20, 2026 · price × 111.6M shares outstanding
- 52-week range
- $81.22 – $171.74 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $283.0M USDMedian day 1.68M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:RVTY · Home | $145.22 USD | -7.21 (-4.7%) | 1,663,061 | $150.93 | $150.93 | $143.61 | $152.43 | Close on Nov 20, 2026 |
| LSE:0KHE | $146.38 USD | -7.27 (-4.7%) | 194 | $150.00 | $151.03 | $145.30 | $153.65 | Close on Nov 20, 2026 |
| Frankfurt:PKN | €135.20 EUR | -2.30 (-1.7%) | — | €133.40 | €135.20 | €133.40 | €137.50 | Close on Nov 20, 2026 |
| B3:R1VT34 | 31.08 BRL | 0.00 (0.0%) | — | 31.08 | 31.08 | 31.08 | 31.08 | Close on Nov 19, 2026 |
| Dusseldorf:PKN | €131.90 EUR | -6.60 (-4.8%) | — | €136.40 | €136.70 | €131.90 | €138.50 | Close on Nov 20, 2026 |
| Munich:PKN | €138.30 EUR | -1.45 (-1.0%) | — | €138.30 | €138.30 | €138.30 | €139.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:RVTY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $145.22 | -7.21 | -4.7% | $150.93 | $150.93 | $143.61 | 1,663,061 | |
| $152.43 | +4.64 | +3.1% | $146.66 | $153.10 | $146.66 | 1,094,180 | |
| $147.79 | -1.06 | -0.7% | $149.22 | $151.43 | $146.84 | 1,511,028 | |
| $148.85 | -5.54 | -3.6% | $153.06 | $153.06 | $147.18 | 1,480,335 | |
| $154.39 | -2.63 | -1.7% | $160.17 | $160.59 | $151.06 | 1,306,667 | |
| $157.02 | -1.23 | -0.8% | $156.51 | $159.36 | $153.04 | 1,467,522 | |
| $158.25 | -0.85 | -0.5% | $161.07 | $163.29 | $158.21 | 1,173,440 | |
| $159.10 | -1.62 | -1.0% | $161.50 | $161.89 | $156.84 | 1,148,653 | |
| $160.72 | +5.61 | +3.6% | $157.44 | $161.93 | $154.15 | 1,722,981 | |
| $155.11 | +4.28 | +2.8% | $150.83 | $158.96 | $149.38 | 1,683,248 | |
| $150.83 | -8.60 | -5.4% | $157.67 | $158.69 | $150.37 | 2,294,936 | |
| $159.43 | -4.05 | -2.5% | $167.69 | $167.69 | $155.96 | 2,860,578 | |
| $163.48 | +11.88 | +7.8% | $163.01 | $171.74 | $162.58 | 3,372,215 | |
| $151.60 | -5.40 | -3.4% | $160.07 | $160.07 | $150.64 | 2,797,680 | |
| $157.00 | -8.78 | -5.3% | $164.21 | $164.21 | $155.81 | 3,179,837 | |
| $165.78 | +0.45 | +0.3% | $165.32 | $167.30 | $163.05 | 1,528,722 | |
| $165.33 | +3.47 | +2.1% | $163.00 | $169.06 | $162.85 | 2,178,407 | |
| $161.86 | +1.47 | +0.9% | $158.82 | $162.76 | $156.28 | 1,551,625 | |
| $160.39 | +1.62 | +1.0% | $159.37 | $161.67 | $159.10 | 1,089,129 | |
| $158.77 | +1.41 | +0.9% | $156.35 | $159.05 | $152.73 | 1,113,400 | |
| $157.36 | +0.75 | +0.5% | $156.18 | $161.64 | $154.87 | 1,779,700 | |
| $156.61 | +0.60 | +0.4% | $154.44 | $159.48 | $152.71 | 1,995,300 | |
| $156.01 | +5.07 | +3.4% | $152.64 | $157.58 | $152.19 | 1,396,700 | |
| $150.94 | -1.70 | -1.1% | $153.89 | $156.87 | $150.71 | 1,259,500 | |
| $152.64 | -2.07 | -1.3% | $154.44 | $155.50 | $151.61 | 1,336,300 | |
| $154.71 | +2.59 | +1.7% | $151.91 | $156.86 | $148.83 | 2,374,800 | |
| $152.12 | -2.96 | -1.9% | $154.26 | $158.00 | $151.45 | 2,023,200 | |
| $155.08 | -0.53 | -0.3% | $156.44 | $157.46 | $153.10 | 1,387,600 | |
| $155.61 | +1.43 | +0.9% | $153.74 | $156.33 | $153.46 | 1,116,000 | |
| $154.18 | +2.02 | +1.3% | $152.40 | $155.50 | $152.40 | 1,224,300 | |
| $152.16 | -1.44 | -0.9% | $152.04 | $152.54 | $146.70 | 1,456,900 | |
| $153.60 | +0.30 | +0.2% | $153.03 | $156.01 | $149.25 | 2,233,600 | |
| $153.30 | -4.06 | -2.6% | $161.62 | $166.25 | $151.45 | 2,678,200 | |
| $157.36 | +5.83 | +3.8% | $151.45 | $157.45 | $150.39 | 1,549,600 | |
| $151.53 | +2.47 | +1.7% | $149.94 | $153.38 | $148.55 | 1,236,600 | |
| $149.06 | -3.83 | -2.5% | $155.48 | $155.48 | $148.31 | 2,483,800 | |
| $152.89 | +0.12 | +0.1% | $153.49 | $158.28 | $152.81 | 4,456,000 | |
| $152.77 | +1.75 | +1.2% | $150.49 | $153.06 | $149.29 | 1,600,100 | |
| $151.02 | -0.09 | -0.1% | $148.97 | $151.05 | $148.12 | 1,500,500 | |
| $151.11 | +0.43 | +0.3% | $150.70 | $151.99 | $147.03 | 1,940,500 | |
| $150.68 | +8.57 | +6.0% | $141.79 | $152.26 | $141.79 | 2,539,900 | |
| $142.11 | -1.20 | -0.8% | $142.40 | $145.00 | $140.08 | 2,244,300 | |
| $143.31 | -0.28 | -0.2% | $143.12 | $144.77 | $141.71 | 2,871,300 | |
| $143.59 | +0.14 | +0.1% | $144.53 | $145.55 | $142.30 | 2,062,000 | |
| $143.45 | -3.28 | -2.2% | $146.50 | $146.89 | $142.45 | 3,321,600 | |
| $146.73 | +1.00 | +0.7% | $147.61 | $149.52 | $145.22 | 2,753,800 | |
| $145.73 | +5.54 | +4.0% | $140.88 | $147.50 | $140.20 | 3,404,200 | |
| $140.19 | +11.70 | +9.1% | $128.67 | $140.22 | $128.67 | 3,693,800 | |
| $128.49 | +4.18 | +3.4% | $124.69 | $128.70 | $123.95 | 1,895,200 | |
| $124.31 | +3.37 | +2.8% | $122.40 | $124.65 | $121.61 | 1,151,500 | |
| $120.94 | -2.91 | -2.3% | $122.77 | $123.23 | $120.90 | 1,344,000 | |
| $123.85 | -3.23 | -2.5% | $125.77 | $126.66 | $121.20 | 1,882,200 | |
| $127.08 | -3.14 | -2.4% | $128.50 | $129.54 | $126.89 | 1,496,200 | |
| $130.22 | -0.41 | -0.3% | $130.03 | $131.70 | $129.56 | 1,175,200 | |
| $130.63 | -0.31 | -0.2% | $132.45 | $133.00 | $127.78 | 1,817,100 | |
| $130.94 | +4.35 | +3.4% | $125.94 | $131.75 | $125.94 | 2,101,500 | |
| $126.59 | -2.08 | -1.6% | $127.46 | $128.18 | $125.49 | 3,056,600 | |
| $128.67 | -0.13 | -0.1% | $127.34 | $128.82 | $125.46 | 1,631,800 | |
| $128.80 | -0.91 | -0.7% | $128.57 | $130.07 | $127.26 | 1,576,300 | |
| $129.71 | +3.36 | +2.7% | $126.53 | $129.80 | $126.50 | 1,932,700 | |
| $126.35 | +1.51 | +1.2% | $123.29 | $126.90 | $123.29 | 1,155,800 | |
| $124.84 | +1.84 | +1.5% | $123.69 | $124.94 | $122.01 | 1,035,600 | |
| $123.00 | -1.75 | -1.4% | $123.49 | $124.89 | $121.38 | 1,505,400 | |
| $124.75 | +0.62 | +0.5% | $124.48 | $124.97 | $121.51 | 2,289,700 | |
| $124.13 | +4.68 | +3.9% | $118.26 | $124.49 | $116.96 | 2,344,500 |
Splits
4 splits since 1980 · NYSE:RVTY · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- NYSE:RVTY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
Latest earnings call · Nov 3, 2026
Revvity (NYSE:RVTY) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 13, 2026
Investor Day (November 2026)
Investor day · 91 slides
Latest news
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
Nov 13, 2026
Closed $154.39 (-1.7%) on Nov 13, 2026
Revvity Announces Financial Results for the Third Quarter of 2026
Nov 3, 2026
Closed $163.48 (+7.8%) on Nov 3, 2026
Revvity Board Declares Quarterly Dividend
Oct 30, 2026
Closed $151.60 (-3.4%) on Nov 2, 2026
Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
Oct 20, 2026
Closed $156.01 (+3.4%) on Oct 20, 2026
Revvity to Present at Upcoming Investor Conferences
Oct 13, 2026
Closed $155.08 (-0.3%) on Oct 13, 2026
Revvity to Hold Earnings Call on November 3, 2026
Oct 2, 2026
Closed $151.53 (+1.7%) on Oct 2, 2026
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
Sep 24, 2026
Closed $150.68 (+6.0%) on Sep 24, 2026
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Sep 9, 2026
Closed $123.85 (-2.5%) on Sep 9, 2026
Quarterly Report for Quarter Ending July 5, 2026 (Form 10-Q)
Aug 11, 2026
Closed $117.88 (+1.9%) on Aug 12, 2026
Revvity Announces Financial Results for the Second Quarter of 2026
Aug 4, 2026
Closed $111.39 (-3.3%) on Aug 4, 2026
Revvity, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 26 in the last 12 months · 47 in all · newest Nov 13, 2026 · oldest 2025
- Calls
- 17 calls with a replay · 17 with a transcript · latest Nov 3, 2026
- Decks
- 34 decks · latest Nov 13, 2026
Where Revvity, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:RVTY · Home listing · This page | NYSE | United States | USD |
| gettex:PKN | gettex | Germany | EUR |
| Tradegate:PKN | Tradegate | Germany | EUR |
| LS Exchange:850943 | LS Exchange | Germany | EUR |
| Lang & Schwarz:850943 | Lang & Schwarz | Germany | EUR |
| Stuttgart:PKN | Stuttgart | Germany | EUR |
| LSE:0KHE | LSE | United Kingdom | USD |
| Frankfurt:PKN | Frankfurt | Germany | EUR |
| B3:R1VT34 | B3 | Brazil | BRL |
| BOATS:RVTY | BOATS | United States | USD |
| BMV:RVTY | BMV | Mexico | MXN |
| Dusseldorf:PKN | Dusseldorf | Germany | EUR |
| Munich:PKN | Munich | Germany | EUR |
| BIVA:RVTY | BIVA | Mexico | MXN |
| Xetra:PKN | Xetra | Germany | EUR |
Valuation
P/E 64.0× against a median of 32.1×: 8th lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Oct 4, 2026 · price Nov 20, 2026
- Enterprise value
- $18.25B USD
- P/E
- 64.0×
- EV/sales
- 6.2×
- EV/EBITDA
- 23.3×
- Price/book
- 2.2×
- Gross margin
- 53.1%
- Operating margin
- 12.7%
- Net margin
- 8.6%
- Debt to equity
- 0.4×
- Beta vs S&P 500
- 1.12
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Revvity, Inc. · NYSE:RVTY | US$16.21B | US$18.25B | 64.0× | 6.2× | 23.3× | 2.2× | 8.6% | 0.4× | 1.12 |
| Wuxi Biologics (Cayman) Inc. · HKEX:2269 | US$21.51B | US$19.96B | 29.2× | 6.1× | 15.9× | 3.0× | 22.5% | 0.1× | n/a |
| Guardant Health, Inc. · NASDAQ:GH | US$19.73B | US$20.20B | n/a | 15.8× | n/a | n/a | −37.9% | n/a | 1.16 |
| Medpace Holdings, Inc. · NASDAQ:MEDP | US$17.08B | US$16.37B | 33.0× | 5.8× | 25.8× | 29.2× | 18.2% | 0.0× | 0.72 |
| Charles River Laboratories International, Inc. · NYSE:CRL | US$15.06B | US$14.86B | 375× | 3.7× | 33.5× | 4.7× | 1.0% | 0.0× | 1.23 |
| ICON plc · NASDAQ:ICLR | US$14.41B | US$16.98B | 32.1× | 2.1× | 15.7× | 1.6× | 5.5% | 0.4× | 1.08 |
| bioMerieux SA · EURONEXT:BIM | US$11.79B | US$11.53B | 27.0× | 2.6× | 10.9× | 2.5× | 9.8% | 0.1× | n/a |
| Bio-Techne Corp · NASDAQ:TECH | US$11.41B | US$11.35B | 66.4× | 9.2× | 33.6× | 5.3× | 14.0% | 0.1× | 0.54 |
| Qiagen N.V. · NYSE:QGEN | US$10.18B | US$11.03B | 24.9× | 5.3× | 15.0× | 3.0× | 19.5% | 0.5× | 0.33 |
| Avantor, Inc. · NYSE:AVTR | US$10.06B | US$13.28B | 29.8× | 2.0× | 14.7× | 1.7× | 5.1% | 0.6× | 0.78 |
| WuXi XDC Cayman, Inc. · HKEX:2268 | US$9.64B | US$8.87B | 43.4× | 9.9× | 33.4× | 5.7× | 24.9% | 0.1× | n/a |
| Median of the others | US$13.10B | US$14.07B | 32.1× | 5.5× | 15.9× | 3.0× | 11.9% | 0.1× | 0.78 |
Forecasts
6 strong buy · 11 hold · 1 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 171.40 USD · Analysts' mean
- EPS, year to Dec 2026
- 5.44 · 17 analysts
- Revenue, year to Dec 2026
- 2.87B · 17 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gene Lay | Senior Vice President, Life Sciences and CEO Advisor |
| Michelle McMurry-Heath | Founder and Chief Executive Officer, BioTechquity Clinical |
| Prahlad R. Singh | President and Chief Executive Officer, Revvity |
| Max Krakowiak | Senior Vice President and Chief Financial Officer |
| Kevin Willoe | President, Revvity Signals Software |
| Michael A. Klobuchar | Chief Operating Officer, Eikon Therapeutics, Inc. |
| Joel Goldberg | Senior Vice President, Administration, General Counsel and Secretary |
| Steve Willoughby | Investor Relations |
| Arvind Sundar-Rajan | Senior Vice President, Chief Digital & Strategy Officer |
| Bryan Kipp | Senior Vice President, Technology and Licensing |
| Craig Monell | Senior Vice President, Reagents |
| Kevin Quick | Vice President of Platforms |
| Madhuri Hegde | Senior Vice President and Chief Scientific Officer |
| Magali Four | Senior Vice President, Chief People and Culture Officer |
| Miriame Victor | Senior Vice President and Chief Business Officer |
| Tajinder Vohra | Senior Vice President, Global Operations |
| Yi-Ping Lin | Senior Vice President, Chief Quality, Regulatory and Clinical Officer |
| Yves Dubaquie | Senior Vice President, Diagnostics |
Board
| Director | Role |
|---|---|
| Alexis P. Michas | Managing Partner, Juniper Investment Company, LLC - Non-Executive Chair |
| Frank Witney | Director |
| Michael A. Klobuchar | Chief Operating Officer, Eikon Therapeutics, Inc. |
| Michel Vounatsos | Director |
| Michelle McMurry-Heath | Founder and Chief Executive Officer, BioTechquity Clinical |
| Pascale Witz | Director |
| Peter Barrett | Partner, Atlas Venture |
| Prahlad R. Singh | President and Chief Executive Officer, Revvity |
| Samuel R. Chapin | Director |
| Sophie V. Vandebroek | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Revvity (NYSE:RVTY) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 7:30 AM ET | Replay |
| Revvity (NYSE:RVTY) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 7:30 AM ET | Replay |
| Revvity (NYSE:RVTY) Q1 2026 Earnings Call | Tue, May 05, 2026 · 7:30 AM ET | Replay |
| Revvity (NYSE:RVTY) Q4 2025 Earnings Call | Mon, Feb 02, 2026 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q3 2025 Earnings Call | Mon, Oct 27, 2025 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q2 2025 Earnings Call | Mon, Jul 28, 2025 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q1 2025 Earnings Call | Mon, Apr 28, 2025 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q4 2024 Earnings Call | Fri, Jan 31, 2025 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q3 2024 Earnings Call | Mon, Nov 04, 2024 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q2 2024 Earnings Call | Mon, Jul 29, 2024 · 8:00 AM ET | Replay |
All 17 calls
| Call | When | Status |
|---|---|---|
| Revvity (NYSE:RVTY) Q1 2024 Earnings Call | Mon, Apr 29, 2024 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q4 2023 Earnings Call | Thu, Feb 01, 2024 · 8:00 AM ET | Replay |
| Revvity (NYSE:RVTY) Q3 2023 Earnings Call | Mon, Oct 30, 2023 · 8:00 AM ET | Replay |
| PerkinElmer, Inc. (PKI) Q4 2022 Earnings Call | Tue, Feb 14, 2023 · 8:00 AM ET | Replay |
| PerkinElmer, Inc. (PKI) Q3 2022 Earnings Call | Tue, Nov 08, 2022 · 8:00 AM ET | Replay |
| PerkinElmer, Inc. (PKI) Q2 2022 Earnings Call | Mon, Aug 01, 2022 · 8:00 AM ET | Replay |
| PerkinElmer, Inc. (PKI) Q1 2022 Earnings Call | Tue, May 03, 2022 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +7.8% |
| Q2 2026 | Aug 4, 2026 · Before open | −3.3% |
| Q1 2026 | May 5, 2026 · Before open | +6.7% |
| Q4 2025 | Feb 2, 2026 · Before open | −1.6% |
| Q3 2025 | Oct 27, 2025 · Before open | −1.8% |
| Q2 2025 | Jul 28, 2025 · Before open | −8.3% |
| Q1 2025 | Apr 28, 2025 · Before open | +0.8% |
| Q4 2024 | Jan 31, 2025 · Before open | −0.6% |
| Q3 2024 | Nov 4, 2024 · Before open | +3.1% |
| Q2 2024 | Jul 29, 2024 · Before open | +9.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 29, 2024 · Before open | +3.5% |
| Q4 2023 | Feb 1, 2024 · Before open | +1.9% |
| Q3 2023 | Oct 30, 2023 · Before open | −16.1% |
| Q2 2023 | Aug 1, 2023 · Before open | −0.3% |
| Q1 2023 | May 11, 2023 · Before open | −5.0% |
| Q4 2022 | Feb 14, 2023 · Before open | −0.5% |
| Q3 2022 | Nov 8, 2022 · Before open | −1.6% |
| Q2 2022 | Aug 1, 2022 · Before open | +5.0% |
| Q1 2022 | May 3, 2022 · After close | +2.8% |
| Q4 2021 | Feb 1, 2022 · After close | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 91 slides | Nov 13, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 9 slides | Nov 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 9 slides | Aug 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 9 slides | May 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 109 slides | May 5, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 11 slides | Feb 2, 2026 |
| J.P. Morgan 44th Healthcare Conference (January 2026) | Conference | 20 slides | Jan 13, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 9 slides | Oct 27, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 9 slides | Jul 28, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 9 slides | Apr 28, 2025 |
All 34 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.86B | 2.76B | 2.75B | 3.31B | 3.83B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B |
| Cost of revenue | 1.34B | 1.43B | 1.43B | 1.55B | 1.55B | 1.79B | 1.59B | 1.44B | 708.7M | 664.8M |
| Gross profit | 1.52B | 1.32B | 1.32B | 1.99B | 2.43B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B |
| Research and development | 215.8M | 196.8M | 216.6M | 221.6M | 200.3M | 146.4M | 189.3M | 194.0M | 139.5M | 124.2M |
| Selling, general and administrative | 991.9M | 994.1M | 1.02B | 1.03B | 975.2M | 716.5M | 815.3M | 811.9M | 626.0M | 590.5M |
| Operating income | 356.6M | 346.7M | 300.6M | 742.7M | 1.26B | 867.3M | 362.0M | 323.9M | 295.6M | 294.6M |
| Depreciation and amortization | 405.3M | 427.8M | 431.8M | 427.0M | 311.4M | 201.6M | 214.0M | 180.6M | 105.0M | 100.0M |
| EBITDA | 762.0M | 774.6M | 732.3M | 1.17B | 1.57B | 1.07B | 576.0M | 504.5M | 400.6M | 394.6M |
| Interest expense | 92.2M | 96.3M | 98.8M | 104.0M | 102.1M | 49.7M | 63.6M | 67.0M | 43.9M | 41.5M |
| Income before tax | 268.3M | 316.1M | 183.0M | 651.8M | 1.20B | 800.1M | 237.1M | 257.7M | 296.7M | 244.1M |
| Income tax | 28.4M | 33.1M | 3.47M | 139.2M | 314.1M | 169.5M | 9.39M | 20.2M | 139.8M | 28.4M |
| Net income | 241.2M | 270.4M | 693.1M | 569.2M | 943.2M | 727.9M | 227.6M | 237.9M | 292.6M | 234.3M |
| Earnings per share, basic | 2.07 | 2.21 | 5.56 | 4.51 | 8.12 | 6.52 | 2.06 | 2.15 | 2.67 | 2.14 |
| Earnings per share, diluted | 2.07 | 2.20 | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 2.64 | 2.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 919.9M | 1.16B | 913.2M | 454.4M | 603.3M | 387.1M | 191.9M | 163.1M | 202.1M | 359.3M |
| Short-term investments | 0 | 689.9M | 0 | |||||||
| Receivables | 744.7M | 632.4M | 632.8M | 612.8M | 707.9M | 1.16B | 725.2M | 632.7M | 552.3M | 425.6M |
| Inventory | 379.5M | 367.6M | 428.1M | 405.5M | 425.9M | 514.6M | 356.9M | 338.3M | 351.7M | 246.8M |
| Current assets | 2.24B | 2.35B | 3.00B | 3.29B | 2.44B | 2.24B | 1.37B | 1.23B | 1.20B | 1.19B |
| Property, plant and equipment | 479.2M | 482.2M | 509.7M | 482.9M | 485.5M | 368.3M | 318.2M | 318.6M | 298.1M | 145.5M |
| Goodwill | 6.61B | 6.46B | 6.53B | 6.48B | 6.63B | 2.64B | 3.11B | 2.95B | 3.00B | 2.25B |
| Total assets | 12.2B | 12.4B | 13.6B | 14.1B | 15.0B | 7.96B | 6.54B | 5.98B | 6.09B | 4.28B |
| Accounts payable | 185.5M | 167.5M | 204.1M | 272.8M | 324.8M | 327.3M | 235.9M | 220.9M | 222.1M | 168.0M |
| Current liabilities | 1.33B | 653.1M | 1.45B | 1.54B | 1.21B | 1.65B | 762.8M | 771.6M | 950.9M | 603.4M |
| Long-term debt | 2.63B | 3.15B | 3.18B | 3.92B | 4.98B | 1.61B | 2.06B | 1.88B | 1.79B | 1.05B |
| Total debt | 3.24B | 3.17B | 3.93B | 4.43B | 5.03B | 2.01B | 2.07B | 1.89B | 2.01B | 1.05B |
| Total liabilities | 4.92B | 4.73B | 5.69B | 6.75B | 7.86B | 4.22B | 3.72B | 3.39B | 3.59B | 2.12B |
| Shareholders' equity | 7.25B | 7.67B | 7.87B | 7.38B | 7.14B | 3.74B | 2.81B | 2.58B | 2.50B | 2.15B |
| Shares outstanding | 112.3M | 120.6M | 123.4M | 126.3M | 126.2M | 112.1M | 111.1M | 110.4M | 110.4M | 109.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 582.9M | 628.3M | 91.3M | 679.8M | 1.41B | 892.2M | 363.5M | 311.0M | 288.5M | 350.6M |
| Capital spending | -73.5M | -86.6M | -81.4M | -85.6M | -86.0M | -63.6M | -76.3M | -93.3M | -39.1M | -31.7M |
| Free cash flow | 509.4M | 541.7M | 9.90M | 594.2M | 1.32B | 828.5M | 287.1M | 217.8M | 249.4M | 318.9M |
| Cash from investing | -17.4M | 776.2M | 1.31B | -132.9M | -4.11B | -504.5M | -487.6M | -159.9M | -1.27B | -83.9M |
| Cash from financing | -857.5M | -1.13B | -947.1M | -661.8M | 2.94B | -202.9M | -150.1M | -179.2M | 782.2M | -115.0M |
| Dividends paid | -32.8M | -34.5M | -35.0M | -35.3M | -32.4M | -31.2M | -31.1M | -31.0M | -30.8M | -30.8M |
| Share buybacks | -820.8M | -369.6M | -388.9M | -80.6M | -73.1M | -6.94M | -6.31M | -57.4M | -3.83M | -151.8M |
| Change in cash | -243.4M | 250.1M | 443.6M | -148.6M | 216.7M | 210.7M | 25.6M | -36.1M | -174.2M | 138.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 25-NSE | Jul 20, 2026 | Other filings | SEC |
| 11-K · Annual report of an employee plan | Jun 23, 2026 | Annual report | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | Jun 1, 2026 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 8-K · Current report | May 1, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 6, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 2, 2026 | Results | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2025 | Results | SEC |
| 8-K · Current report | Oct 24, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2025 | Results | SEC |
| 11-K · Annual report of an employee plan | Jun 20, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 144 · Notice of proposed sale | May 29, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2025 | Results | SEC |
| 8-K · Current report | Apr 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 12, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 12, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 12, 2025 | Meeting notice | SEC |
| S-3ASR · Registration statement | Feb 28, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Feb 26, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 7, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 4, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Oct 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Aug 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2024 | Results | SEC |
| 11-K · Annual report of an employee plan | Jun 27, 2024 | Annual report | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 7, 2024 | Other filings | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| 144 · Notice of proposed sale | May 15, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2024 | Results | SEC |
| 8-K · Current report | Apr 24, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 13, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 13, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 13, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2024 | Other filings | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Revvity, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 111,638,757
- Fully diluted
- 111,638,757
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 111,638,757 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 111,638,757 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gregory L. Summe Other companies: Wheels Up Experience Inc. (Director · Since at least Aug 7, 2024); GRAIL, Inc. (Director · Since at least Jun 21, 2024); Avantor, Inc. (Director · Since at least May 7, 2020); NXP Semiconductors N.V. (Director · Since at least Aug 1, 2019); Virgin Orbit Holdings Inc (Director · Apr 13, 2021 – Apr 13, 2021 · Past); NextGen Acquisition Corp. II (Director · Mar 22, 2021 – Mar 22, 2021 · Past); Xos, Inc. (Director · Oct 6, 2020 – Oct 6, 2020 · Past); Freescale Semiconductor Ltd (Director · Sep 5, 2014 – Dec 7, 2015 · Past); LMI Aerospace Inc (Director · Jul 21, 2014 – Jun 27, 2017 · Past); Automatic Data Processing, Inc. (Director · Sep 10, 2007 – Nov 25, 2013 · Past); State Street Corporation (Director · Apr 19, 2006 – Feb 18, 2025 · Past) | Exe. Chairman of the Board, Director · Jan 31, 2006 – Feb 27, 2009 · Past |
| Vicki Sato Other companies: Allogene Therapeutics, Inc. (Director · Since at least Jul 30, 2021); Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jan 2, 2025 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 11, 2019 · Past); BorgWarner Inc. (Director · Feb 12, 2014 – Apr 29, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2010 · Past); Bristol-Myers Squibb Company (Director · Jul 11, 2006 – Feb 1, 2021 · Past) | Director · May 2, 2006 – Feb 9, 2017 · Past |
| Jeffrey Capello Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least Jun 13, 2023); Neogen Corporation (Director · Since at least Sep 2, 2022); Biogen Inc. (EVP & Chief Financial Officer · Dec 11, 2017 – Feb 12, 2020 · Past); Decoy Therapeutics Inc. (Director · Apr 1, 2015 – Jul 26, 2017 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Jul 4, 2018 · Past); Boston Scientific Corporation (EVP & Chief Financial Officer · Jun 16, 2008 – Nov 27, 2013 · Past); Sirtris Pharmaceuticals Inc (Director · Jan 2, 2008 – Jan 2, 2008 · Past) | SVP & CFO · Jan 31, 2006 – Jan 29, 2008 · Past |
| Patrick J Sullivan Other companies: Insulet Corporation (CEO and Chairman of the Board, Director · Sep 16, 2014 – Mar 29, 2018 · Past); Beacon Financial Corporation (EVP · Jul 21, 2011 – Jan 30, 2013 · Past); Legacy Bancorp Inc (President, Director · Apr 1, 2010 – Dec 31, 2010 · Past); Santander Holdings USA Inc (EVP & Mnging Dir. Comm. Bank · Jan 7, 2008 – Mar 3, 2008 · Past); Hologic Inc (Executive Chairman, Director · Oct 22, 2007 – May 28, 2008 · Past); Adeza Biomedical Corp (Director · Mar 19, 2007 – Mar 19, 2007 · Past); Cytyc Corp (Chief Executive Officer · Jan 24, 2006 – Oct 22, 2007 · Past) | Director · Feb 25, 2008 – Apr 30, 2019 · Past |
| Alexis P. Michas Other companies: AstroNova, Inc. (Director · Since at least Jun 14, 2022); BorgWarner Inc. (Director · Since at least Feb 8, 2006); Allient Inc. (Director · May 6, 2015 – May 3, 2017 · Past); Airtran Holdings Inc (Director · May 24, 2006 – May 18, 2010 · Past); Lincoln Educational Services Corporation (Director · May 23, 2006 – May 1, 2015 · Past) | Managing Partner, Juniper Investment Company, LLC - Non-Executive Chair · Since at least May 2, 2006 |
| Kevin Hrusovsky Other companies: 908 Devices Inc. (Director · Since at least Dec 17, 2020); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 27, 2021 · Past); Quanterix Corporation (Executive Chairman, Director · Dec 6, 2017 – Jul 5, 2022 · Past); SeraCare Life Sciences Inc (Director · May 10, 2011 – Apr 20, 2012 · Past); Caliper Life Sciences Inc (President & CEO, Director · Mar 3, 2009 – Nov 7, 2011 · Past) | See Remarks · Feb 1, 2012 – May 31, 2013 · Past |
| Robert F. Friel Other companies: West Pharmaceutical Services, Inc. (Director · Since at least Feb 17, 2020); Xylem Inc. (Chair, Xylem Inc. Former Chairman, President & CEO, PerkinElmer, Inc. · Since at least Dec 12, 2012); NuVasive Inc (Director · Feb 12, 2016 – Sep 1, 2023 · Past); CareFusion Corp (Director · Aug 31, 2009 – Mar 17, 2015 · Past); Millennium Pharmaceuticals Inc (Director · May 1, 2006 – May 14, 2008 · Past) | Chairman and CEO, Director · Jan 31, 2006 – Feb 13, 2019 · Past |
| Frank A. Wilson Other companies: Novanta Inc. (Member of Board of Directors · Since at least May 13, 2021); Alkermes plc (Director · Since at least Sep 12, 2019); Cabot Corporation (Director · Since at least Sep 13, 2018); Sparton Corporation (Director · Mar 4, 2019 – Mar 4, 2019 · Past) | Please See Remarks · Dec 7, 2017 – Mar 5, 2018 · Past |
| Frank R. Witney Other companies: Alamar Biosciences, Inc. (Director · Since at least Apr 16, 2026); Standard BioTools Inc. (Director · Since at least Jun 28, 2024); Cerus Corporation (Director · Since at least May 9, 2024); Telesis Bio, Inc. (Director · Jul 6, 2023 – Jul 6, 2023 · Past) | Director · Since at least May 1, 2024 |
| John A. Roush Other companies: Advanced Energy Industries, Inc. (Director · Since at least May 5, 2016); LeMaitre Vascular, Inc. (Director · Since at least Apr 9, 2014); ESS Tech, Inc. (Chief Financial Officer, Director · Sep 16, 2020 – Oct 8, 2021 · Past); Novanta Inc. (Chief Executive Officer, Director · Dec 14, 2010 – Sep 1, 2016 · Past) | Senior Vice President · Jan 31, 2006 – Feb 9, 2010 · Past |
All 45 people
| Person | Seat |
|---|---|
| Pascale Witz Other companies: Regulus Therapeutics Inc (Director · Since at least Jun 1, 2017); Tesaro Inc (Director · May 10, 2018 – Jan 22, 2019 · Past); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past) | Director · Since at least Oct 27, 2017 |
| Peter Barrett Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026); Synlogic Inc (Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022); Larimar Therapeutics, Inc. (Director · May 10, 2022 – May 10, 2022 · Past) | Partner, Atlas Venture · Since at least May 6, 2022 |
| Samuel R. Chapin Other companies: PHINIA Inc. (Director · Since at least Jul 3, 2023); O-I Glass, Inc. (Director · Since at least May 12, 2021); CIRCOR International Inc (Director · Mar 17, 2021 – Oct 18, 2023 · Past) | Director · Since at least May 7, 2021 |
| Sylvie Grégoire Other companies: CervoMed Inc. (Co-Founder · Since at least Aug 16, 2023); Idm Pharma Inc (Director · Jun 14, 2006 – Jun 14, 2007 · Past); Cubist Pharmaceuticals Inc (Director · Jun 9, 2006 – Jun 10, 2010 · Past) | Director · Feb 6, 2015 – May 15, 2023 · Past |
| Daniel R Marshak Other companies: InVivo Therapeutics Holdings Corp (Director · Sep 29, 2014 – Nov 17, 2022 · Past); Cambrex Corporation (Vice President · Jan 26, 2006 – Feb 27, 2006 · Past) | SVP & CSO · Apr 22, 2008 – Sep 26, 2014 · Past |
| Michael A. Klobuchar Other companies: Eikon Therapeutics, Inc. (Chief Operating Officer · Since at least Feb 4, 2026); Merck & Company, Inc. (EVP - Chief Strategy Officer · Jul 5, 2021 – May 4, 2024 · Past) | Chief Operating Officer, Eikon Therapeutics, Inc. · Since at least Feb 1, 2024 |
| Michel Vounatsos Other companies: Zai Lab Ltd. (Director · Since at least Jan 7, 2023); Biogen Inc. (Director · Apr 18, 2016 – Nov 5, 2026 · Past) | Director · Since at least Mar 1, 2020 |
| Sophie V. Vandebroek Other companies: IDEXX Laboratories, Inc. (Director · Since at least Jul 15, 2013); Analogic Corporation (Director · Aug 1, 2008 – Feb 2, 2015 · Past) | Director · Since at least Feb 1, 2024 |
| Frank Witney Other companies: Cerus Corporation (Lead Independent Director · Since at least Mar 16, 2026) | Director · Since at least May 11, 2026 |
| Michelle McMurry-Heath Other companies: Bioventus Inc. (Director · Since at least Jan 1, 2022) | Founder and Chief Executive Officer, BioTechquity Clinical · Since at least Jul 22, 2022 |
| Prahlad Singh Other companies: Amphenol Corporation (Director · Since at least Jan 12, 2023) | President and Chief Executive Officer, Revvity · Since at least Oct 3, 2016 |
| Tajinder Vohra Other companies: Genpact Limited (Senior Vice President · Aug 1, 2007 – Feb 17, 2010 · Past) | Senior Vice President, Global Operations · Since at least Jan 29, 2018 |
| Andrew Okun | Please See Remarks · Apr 26, 2011 – Apr 13, 2023 · Past |
| Anita Gonzales | VP and CAO · Since at least May 13, 2023 |
| Arvind Sundar-Rajan | Senior Vice President, Chief Digital & Strategy Officer · Since at least Nov 4, 2026 |
| Bryan Kipp | Senior Vice President, Technology and Licensing · Since at least Nov 10, 2025 |
| Craig Monell | Senior Vice President, Reagents · Since at least Aug 6, 2025 |
| Daniel R Tereau | Please See Remarks · Feb 1, 2016 – Feb 5, 2024 · Past |
| Deborah A Butters | Please See Remarks · Jul 11, 2016 – Feb 7, 2020 · Past |
| Gabriel Schmergel | Director · Feb 15, 2006 – Feb 16, 2012 · Past |
| Gene Lay | Senior Vice President, Life Sciences and CEO Advisor · Since at least Nov 4, 2026 |
| James Corbett | Please See Remarks · Feb 1, 2012 – Apr 30, 2019 · Past |
| Joel Goldberg | Senior Vice President, Administration, General Counsel and Secretary · Since at least Jul 21, 2008 |
| John R Letcher | See Remarks · Feb 1, 2010 – Jun 5, 2015 · Past |
| Katherine A OHara | SVP, Gen. Counsel, & Secretary · Jan 31, 2006 – Jan 29, 2008 · Past |
| Kevin Quick | Vice President of Platforms · Since at least Apr 16, 2026 |
| Kevin Willoe | President, Revvity Signals Software · Since at least Oct 20, 2026 |
| Madhuri Hegde | Senior Vice President and Chief Scientific Officer · Since at least Oct 2, 2025 |
| Magali Four | Senior Vice President, Chief People and Culture Officer · Since at least Nov 4, 2026 |
| Max Krakowiak | Senior Vice President and Chief Financial Officer · Since at least Oct 2, 2026 |
| Maxwell Krakowiak | Please See Remarks · Since at least Feb 5, 2024 |
| Miriame Victor | Senior Vice President and Chief Business Officer · Since at least Feb 5, 2024 |
| Steve Willoughby | Investor Relations · Since at least Oct 2, 2026 |
| Yi-Ping Lin | Senior Vice President, Chief Quality, Regulatory and Clinical Officer · Since at least Nov 4, 2026 |
| Yves Dubaquie | Senior Vice President, Diagnostics · Since at least Jun 2, 2025 |
Log in to ask 6ix AI your own questions about Revvity, Inc.